William Blair analyst Tim Lugo downgraded VistaGen Therapeutics (NASDAQ: VTGN) from Outperform to Market Perform, as the company announced failure ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE